News & Updates
FDA approvals, clinical trial results, and pipeline moves across GLP-1s and peptides. Each update breaks down what the data actually shows, not just the headline.
Retatrutide for Type 2 Diabetes: TRANSCEND-T2D-1
TRANSCEND-T2D-1: retatrutide cut A1C by up to 2.0 points and produced up to 16.8% weight loss in 537 adults with type 2 diabetes over 40 weeks.
Jul 19, 2026FDA Peptide Panel Conflict of Interest
STAT and CNN reporting found several new FDA panel members voting July 23-24 on BPC-157 and TB-500 run or promote peptide businesses themselves.
Jul 19, 2026BPC-157 and TB-500: FDA Hearing July 2026
The FDA Pharmacy Compounding Advisory Committee will review BPC-157, TB-500, and 5 other peptides for the 503A compounding list on July 23-24, 2026.
Jul 19, 2026FDA Staff Recommend Against BPC-157, TB-500
FDA briefing documents posted June 30, 2026 recommend against adding BPC-157, TB-500, and 5 other peptides to the 503A compounding list.
Jul 13, 2026Generic Tirzepatide: FDA Review and Patent Timeline
Sandoz and Amneal both filed ANDAs for generic tirzepatide in 2026, but Eli Lilly patents run to 2036. Here is what FDA acceptance actually means.
Jul 4, 2026CagriSema for Type 2 Diabetes: REIMAGINE Results
REIMAGINE 2: CagriSema cut HbA1c 1.91 points more than semaglutide alone and produced 14.2% weight loss in 2,728 adults with type 2 diabetes.
Jun 30, 2026What Is Aleniglipron?
Structure Therapeutics' oral GLP-1 pill posted 16.3% placebo-adjusted weight loss in Phase 2 ACCESS II with no fasting window required.
Jun 29, 2026Is Compounded Tirzepatide Legal in 2026?
FDA proposed April 30 to permanently ban 503B bulk compounding of tirzepatide and semaglutide. Comment period closes June 29. 503A window remains narrow.
Jun 25, 2026Survodutide MASLD Phase 3 Results
SYNCHRONIZE-MASLD: survodutide normalized liver fat in 61% of patients with fatty liver disease at 48 weeks.
Jun 24, 2026CagriSema vs Tirzepatide
REDEFINE 4: tirzepatide won 25.5% to 23% at 84 weeks, and CagriSema failed to meet the non-inferiority threshold.
Jun 22, 2026GLP-1 Hair Loss: Tirzepatide vs Semaglutide
2026 TriNetX cohort: tirzepatide RR 1.68, semaglutide RR 1.43 for nonscarring hair loss vs metformin. Mechanism, timeline, and what helps.
Jun 18, 2026Berobenatide: Once-Monthly GLP-1 Shot
Pfizer's berobenatide posted 12.3% placebo-adjusted weight loss with monthly maintenance dosing in Phase 2b VESPER trials at ADA 2026.
Jun 15, 2026Wegovy HD: Semaglutide 7.2mg Results
STEP UP trial: semaglutide 7.2mg delivered 20.7% weight loss, closing the gap with tirzepatide.
Jun 13, 2026Survodutide SYNCHRONIZE-1 Results
SYNCHRONIZE-1: 16.6% weight loss, 34% less visceral fat, 63% less liver fat in 76-week Phase 3 trial.
Jun 11, 2026GLP-1 Drugs and Heart Failure
SOUL trial: oral semaglutide cut MACE by 14% and heart failure events by 22% in 9,647 high-risk T2D patients.
Jun 10, 2026GLP-1 Drugs and Alzheimer's
EVOKE and EVOKE+ enrolled 3,808 people for two years: oral semaglutide made no difference on Alzheimer's progression.
Jun 8, 2026Medicare GLP-1 Coverage Starting July 2026
The Medicare GLP-1 Bridge covers Wegovy, Zepbound, and Foundayo for $50/month starting July 1.
Jun 7, 2026Semaglutide FDA Approval for Kidney Disease
FLOW trial: 24% lower risk of kidney failure, 29% lower cardiovascular death.
Jun 6, 2026GLP-1s and Muscle Loss
How much GLP-1 weight loss is muscle, and how to protect it.
Jun 5, 2026GLP-1 MASH Liver Approval
Semaglutide becomes the first GLP-1 approved for MASH.
Jun 1, 2026Retatrutide TRIUMPH Phase 3 Results
TRIUMPH-1: 28.3% mean weight loss at 80 weeks.
Jun 1, 2026Tirzepatide for Sleep Apnea
SURMOUNT-OSA: up to 63% lower sleep apnea severity.
Jun 1, 2026Switching to Oral Orforglipron
Switching from injections to the oral orforglipron pill.
May 6, 2026GLP-1s and Addiction
Large studies link GLP-1s to lower alcohol use disorder.
May 6, 2026BPC-157 FDA Reclassification
The 2026 FDA reclassification of BPC-157, TB-500, and GHK-Cu.
May 6, 2026The Five-Target Obesity Drug
A five-target molecule posting 40% weight loss in mice.
